Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

pxs-5505

  • Home
  •  
  • pxs-5505



  • Most Read
  • Latest Comments
  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Pandemic poses opportunity to online learning platform OpenLearning
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Novatti partners with Ripple for global blockchain payments network
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • Opinion

    Is ASX: OOO the riskiest or smartest oil investment?
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    Crowd Media adds voice cloning for immersive celebrity experiences in AI deal
    • Review
    • January 27, 2021
  • Research Note - Rise of the Cashless Economy
    • Review
    • June 3, 2020
  • Novatti to drive Malaysia into the digital payments era with ATX acquisition
    • Review
    • October 20, 2021
  • Apiam expands equine vet footprint in Queensland in time for breeding season
    • Review
    • June 30, 2021
  • Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials
    • Review
    • March 24, 2020

Latest Articles

  • Fibrosis is the simple disease process that’s more important than you think
    Fibrosis is the simple disease process that’s more important than you think
    • News

  • The Cancer Index: Why investing in oncology biotechs is more science than art
    The Cancer Index: Why investing in oncology biotechs is more science than art
    • News

  • “Scars are more than skin deep”: Why Professor Fiona Wood is working with this biotech to melt away scars
    “Scars are more than skin deep”: Why Professor Fiona Wood is working with this biotech to melt away scars
    • News

  • International expansion as more hospitals register for Pharmaxis’ cancer treatment trials
    International expansion as more hospitals register for Pharmaxis’ cancer treatment trials
    • News

  • Out-the-box thinkers are just what the myelofibrosis treatment market needs
    Out-the-box thinkers are just what the myelofibrosis treatment market needs
    • News

  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Fibrosis is the simple disease process that’s more important than you think

    How does a company with a lead asset cancer drug also get into dermatology?  What does blood cancer and keloid scars have in common?  The answer is: fibrosis.  Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how

    Read More
    Public
  • International expansion as more hospitals register for Pharmaxis’ cancer treatment trials
    • News

    International expansion as more hospitals register for Pharmaxis’ cancer treatment trials

    Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,

    Read More
    Public
  • Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug
    • News

    Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug

    In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline.  For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the

    Read More
    Public
  • First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed
    • News

    First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

    Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir.   Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.